AU2021329529A1 - Compositions and methods for neurological diseases - Google Patents

Compositions and methods for neurological diseases Download PDF

Info

Publication number
AU2021329529A1
AU2021329529A1 AU2021329529A AU2021329529A AU2021329529A1 AU 2021329529 A1 AU2021329529 A1 AU 2021329529A1 AU 2021329529 A AU2021329529 A AU 2021329529A AU 2021329529 A AU2021329529 A AU 2021329529A AU 2021329529 A1 AU2021329529 A1 AU 2021329529A1
Authority
AU
Australia
Prior art keywords
receptor
engineered
neuron
seq
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021329529A
Other languages
English (en)
Other versions
AU2021329529A9 (en
Inventor
Orion P. KEIFER, Jr.
Anthony LAU, Jr.
Stefanie MAKINSON
Alexander NAKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trames Bio Inc
Original Assignee
Trames Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trames Bio Inc filed Critical Trames Bio Inc
Publication of AU2021329529A1 publication Critical patent/AU2021329529A1/en
Publication of AU2021329529A9 publication Critical patent/AU2021329529A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021329529A 2020-08-21 2021-08-20 Compositions and methods for neurological diseases Pending AU2021329529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068890P 2020-08-21 2020-08-21
US63/068,890 2020-08-21
PCT/US2021/046915 WO2022040535A2 (en) 2020-08-21 2021-08-20 Compositions and methods for neurological diseases

Publications (2)

Publication Number Publication Date
AU2021329529A1 true AU2021329529A1 (en) 2023-04-27
AU2021329529A9 AU2021329529A9 (en) 2025-03-13

Family

ID=80350587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021329529A Pending AU2021329529A1 (en) 2020-08-21 2021-08-20 Compositions and methods for neurological diseases

Country Status (11)

Country Link
US (1) US20240317834A1 (https=)
EP (1) EP4200020A4 (https=)
JP (1) JP2023538130A (https=)
KR (1) KR20230061409A (https=)
CN (1) CN116802201A (https=)
AU (1) AU2021329529A1 (https=)
BR (1) BR112023003167A2 (https=)
CA (1) CA3192604A1 (https=)
IL (1) IL300816A (https=)
MX (1) MX2023002161A (https=)
WO (1) WO2022040535A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487904B (zh) * 2023-12-28 2024-05-31 湖南家辉生物技术有限公司 Gabrb3基因突变体、突变体蛋白、试剂、试剂盒及应用
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304040B2 (en) * 2016-07-07 2024-09-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US10538571B2 (en) * 2017-11-27 2020-01-21 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
AU2020334147A1 (en) * 2019-08-21 2022-03-31 Trames Bio, Inc. Compositions and methods for neurological diseases

Also Published As

Publication number Publication date
WO2022040535A3 (en) 2022-03-31
EP4200020A2 (en) 2023-06-28
BR112023003167A2 (pt) 2023-05-02
US20240317834A1 (en) 2024-09-26
AU2021329529A9 (en) 2025-03-13
EP4200020A4 (en) 2024-11-20
MX2023002161A (es) 2023-05-18
CN116802201A (zh) 2023-09-22
JP2023538130A (ja) 2023-09-06
KR20230061409A (ko) 2023-05-08
IL300816A (en) 2023-04-01
WO2022040535A2 (en) 2022-02-24
CA3192604A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US10538571B2 (en) Compositions and methods for neurological diseases
JP7781052B2 (ja) 神経学的疾患のための組成物および方法
AU2021329529A1 (en) Compositions and methods for neurological diseases
WO2023159208A2 (en) Compositions and methods for neurological diseases
AU2023221946A1 (en) Ligand gated ion channels and methods of use
BR122025015501A2 (pt) Receptor modificado, polinucleotídeo, vetor, uso dos mesmos, bem como método para expressão de um receptor modificado em um neurônio
CN119343455A (zh) 用于治疗癫痫和神经性疼痛的表达盒

Legal Events

Date Code Title Description
SREP Specification republished